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Apoptosis and myostatin are major mediators of muscle
atrophy and might therefore be involved in the wasting of
uremia. To examine whether they are expressed in the
skeletal muscle of patients with chronic kidney disease (CKD),
we measured muscle apoptosis and myostatin mRNA and
their related intracellular signal pathways in rectus abdominis
biopsies obtained from 22 consecutive patients with stage 5
CKD scheduled for peritoneal dialysis. Apoptotic loss of
myonuclei, determined by anti-single-stranded DNA
antibody and terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling assays, was significantly
increased three to fivefold, respectively. Additionally,
myostatin and interleukin (IL)-6 gene expressions were
significantly upregulated, whereas insulin-like growth factor-I
mRNA was significantly lower than in controls.
Phosphorylated JNK (c-Jun amino-terminal kinase) and its
downstream effector, phospho-c-Jun, were significantly
upregulated, whereas phospho-Akt was markedly
downregulated. Multivariate analysis models showed that
phospho-Akt and IL-6 contributed individually and
significantly to the prediction of apoptosis and myostatin
gene expression, respectively. Thus, our study found
activation of multiple pathways that promote muscle atrophy
in the skeletal muscle of patients with CKD. These pathways
appear to be associated with different intracellular signals,
and are likely differently regulated in patients with CKD.
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Chronic kidney disease (CKD) is associated with a wasting
syndrome, which directly correlates with mortality and
morbidity.1 The risk of wasting progressively increases as
the glomerular filtration rate decreases,2 with a high
incidence of this complication in patients who are at the
beginning of dialytic treatment.2,3 Several conditions asso-
ciated with CKD, such as a decrease in nutrient intake,
metabolic acidosis, physical inactivity, diabetes, and sepsis
can promote muscle wasting through an increase in protein
degradation and/or a decrease in protein synthesis.3–7
However, it is increasingly apparent that uremia per se
predisposes to wasting.4,5 Recent advances obtained in
experimental uremia have consistently increased our under-
standing of intracellular pathways producing loss of muscle
mass. Acidosis increases protein degradation through an
upregulation of the ATP-dependent, ubiquitin-requiring
pathway.6–8 In addition, impaired signaling through the
insulin receptor substrate-1/phosphoinositide 3 (PI3)-kinase/
Akt pathway can predispose to catabolism through the
upregulation of atrogin-related proteolytic pathways9,10
(Figure 1).
A new, emerging concept is the role of apoptosis in the
regulation of muscle size and function in physiology and
disease.11,12 During atrophy, nuclei are lost by apoptosis,
whereas during hypertrophy, new nuclei are added to the
fibers from muscle stem cells (satellite cells).11,12 It must be
noted that the same signal can theoretically cause cell and
protein loss, as Akt can mediate the effects of PI3-kinase on
different events, such as apoptosis13–15 and protein catabo-
lism15 (Figure 1). These multiple effects may be particularly
injurious in uremia, in which impaired insulin-like growth
factor I (IGF-I) signaling not only leads to abnormal protein
metabolism in the muscle but also impairs the proliferation
of satellite cells.16,17 It is noteworthy that a change in the
balance between IGF-I and myostatin, a negative regulator of
skeletal muscle mass, has been observed in experimental
uremia.18,19 The potential importance of myostatin has been
underscored by studies obtained in humans, in which muscle
myostatin has been shown to increase with aging, in muscle
atrophy and in chronic illnesses.20,21 However, we do not
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know how myostatin is regulated in CKD patients and
whether it may contribute to wasting. In contrast to findings
obtained in uremic rats, Wang et al.22 observed that muscle
myostatin mRNA transcripts were normally expressed and
that they normally declined after physical exercise in the
muscle of patients on maintenance hemodialysis.
In this study, we examined whether apoptosis and
myostatin can contribute to the development of muscle
wasting by studying their expression in muscle biopsies of
patients with severe (stage 5) CKD. In addition, we studied
the role of several other factors, including Akt signaling and
inflammatory mediators, as potential predictors of muscle
apoptotic changes and myostatin expression. Our data show
that in patients with CKD, at an advanced stage, both
apoptosis and myostatin are upregulated in the skeletal
muscle, suggesting that both factors might have a role in
muscle wasting. However, apoptosis and myostatin seem to
be related to different effectors, suggesting that they are
differently regulated in the muscle of CKD patients.
RESULTS
Apoptotic changes are enhanced in the skeletal muscle
of CKD patients
In this study, we used two different methods to evaluate
apoptotic changes in the skeletal muscle. As a reference
method, apoptosis was detected by an assay, which is
based on monoclonal antibodies to single-stranded DNA
(ssDNA). The percentage of apoptotic cells was low in
control subjects (1.30±0.2%), but the number of nuclei
with the anti-ssDNA-positive signal was markedly increased
in the skeletal muscle of CKD patients (an approximately
five-fold increase, Po0.001 vs controls) (Figure 2a–c). As a
second step, we used terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) to detect
apoptosis. Although commonly used for detection of
apoptosis in the skeletal muscle,12 TUNEL seems to be less
specific than the anti-ssDNA antibody technique, as it also
detects necrotic and autolytic types of cell death.23 In
addition, the sensitivity of TUNEL seems to be low in
the detection of early apoptotic changes as compared
with the anti-ssDNA technique, as it detects late stages of
apoptosis associated with low-molecular-weight DNA
fragmentation.23,24Again, the number of cells with a TU-
NEL-positive signal was threefold increased (Po0.05 vs
controls) in patients with CKD (Figure 3). Therefore, an
increase in apoptosis was clearly shown and qualitatively
evident by both techniques.
To verify which cellular type (myonuclei or satellite cells)
was implicated in apoptosis, we considered both morpholo-
gical criteria (that is, the anatomical location inside or outside
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Figure 1 | Scheme of mechanisms controlling the PI3-kinase/Akt pathway, a major regulator of skeletal muscle protein content and
size. This pathway is initiated by the activation of PI3-kinase, which phosphorylates Akt, leading to the regulation of mTOR kinases and
protein synthesis. Many of the effects mediated by IGF-I and insulin on muscle growth are activated through this pathway. In addition, p-Akt
has an inhibitory effect on protein degradation, by acting on atrogin-1, MuRF-1, and caspase-3. In addition, p-Akt has a major anti-apoptotic
effect. Decreased activity in the PI3-kinase/Akt pathway (such as during insulin/IGF-I resistance, uremia, and metabolic acidosis) facilitates
muscle atrophy through reduced protein synthesis and augmented protein degradation. A decrease in p-Akt may also derive from
upregulation of JNK due to activation of cytokine receptor(s) or endoplasmic reticulum stress in the presence of oxidative stress and
inflammation. Myostatin, a member of the transforming growth factor (TGF)-b superfamily, is also an important regulator of muscle size.
Myostatin inhibits muscle cell proliferation and myoblast differentiation. In addition, overexpressing myostatin results in cachexia by
increased protein degradation because of upregulation of atrogin-1 and MuRF-1. Myostatin activity seems to be linked to the PI3-kinase/Akt
pathway, suggesting that a change in the balance between the PI3-kinase/Akt pathway and the myostatin-dependent pathway can push
the skeletal muscle toward hypertrophy or atrophy. IGF-I, insulin-like growth factor I; IRS, insulin receptor substrate; JNK, c-Jun amino-
terminal kinase; MAPK, mitogen-activated protein kinase; MuRF1, muscle ring finger; mTOR, mammalian target of rapamycin; p-Akt,
phosphorylated Akt; PI3-kinase, phosphatidylinositol 3-kinase; TGF-b, transforming growth factor-b; |- - -, inhibition.
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the basilar lamina) and the expression of transcription factors,
such as MyoD and C-met. C-met is expressed in quiescent,
activated, and proliferating satellite cells, whereas MyoD is
expressed in activated and proliferating satellite cells.25 We
observed between 3 and 4% MyoD-positive or C-met-positive
cells in patients and controls (P¼NS). By double immu-
noassay (ssDNA/c-met), we found a similar percentage of
ssDNAþ /C-metþ (0.7±0.5% and 0.9±0.3%, respectively, in
patients and controls) and ssDNAþ /MyoDþ (0.5±0.5% and
0.6±0.3%, respectively, in patients and controls) satellite cell
nuclei (P¼NS). These findings indicate that most of the
apoptotic nuclei were myonuclei.
As a trend, muscle-fiber cross-sectional area (CSA) was
lower in patients (CKD patients median¼ 990 mm2, range
735–1555; controls median¼ 1416 mm2, range 1090–1924)
(Po0.07).
Myostatin and IGF-I are differently expressed in the skeletal
muscle of CKD patients
Figure 4 illustrates the changes in myostatin mRNA
expression. It must be noted that there was a greater than
three-fold increase in myostatin mRNA levels in the muscle
of CKD patients compared with age-matched control
subjects (Po0.05). In addition, the myostatin immunohis-
tochemical signal (expressing both the amount of protein
and its distribution) was very low in controls, but it was
clearly expressed in CKD patients. Myostatin displayed a
diffuse signal in fiber cytoplasms and in the nuclei (Figure 4d,
f, and g). In some cases, the immunoreactivity of myostatin
was observed to be associated with the sarcolemma (Figure 4e),
suggesting that myostatin is released in the plasma.
Patients with CKD displayed significantly reduced mRNA
and protein levels for IGF-I (Figure 5). We previously
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Figure 2 | In situ detection of muscle cell apoptosis by ssDNA antibody analysis. Compared with control subjects, a distinct increase in
the incidence of muscle cell apoptosis is evident in the CKD muscle. (a, b) Black arrows point to nuclei that display ssDNA positivity (original
magnification  400–1000). (c) Quantitation of muscle cell apoptosis in CKD patients and controls. The apoptotic rate was expressed
as the percentage of ssDNA-positive nuclei per total nuclei (apoptotic plus non-apoptotic nuclei) (aPo0.001 vs controls, mean±s.e.m.).
CKD, chronic kidney disease; ssDNA, single-stranded DNA.
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Figure 3 | In situ detection of muscle cell apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL). (a, b) Serial sections of healthy and CKD muscles were stained for apoptosis using the TUNEL technique. Apoptotic nuclei (black
arrows) are more evident in CKD with respect to controls (original magnification  400–1000). (c) The apoptotic rate was expressed
as the percentage of TUNEL-positive nuclei per total nuclei (apoptotic plus non-apoptotic nuclei) (aPo0.05 vs controls, mean±s.e.m.).
CKD, chronic kidney disease.
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observed an upregulation of interleukin (IL)-6 mRNA in the
skeletal muscle of CKD patients displaying an inflammatory
response.26 In this study, IL-6 mRNA signal was very faint in
the muscle tissue from healthy subjects, but it was three to
sixfold increased in CKD patients (Po0.05, data not shown).
To further understand whether IL-6 could be produced by
infiltrating macrophages, we studied CD68 staining of muscle
serial sections. CD68 staining showed a similar number of
macrophages infiltrating the muscle in CKD patients and
controls (14±2 cells/mm2 vs 12±2 cells/mm2 CSA in
patients and controls, respectively). Rheumatoid synovia
was used as positive control.
Upregulation of p-JNKand its downstream effector, p-c-Jun
As JNK (c-Jun amino-terminal kinase) signaling constitutes a
major component of apoptotic signaling in the skeletal
muscle in aging27 and after injury,28 we studied the
expression and localization of phosphorylated JNK (p-JNK)
and its downstream effector, activated (phosphorylated)
c-Jun. P-JNK expression was present in the normal muscle
at minimal levels. Conversely, p-JNKwas upregulated in CKD
patients (Figure 6a and b). Next, we studied the muscle
nuclear expression of p-c-Jun, a main substrate of JNK and
also a member of the heterodimeric activating protein-1
transcription factor family, which is phosphorylated by JNK
at serine 63 and 73. In the control tissue (Figure 6c), p-c-Jun
was expressed in minimal amounts. Conversely, the percen-
tage of p-c-Jun-positive nuclei was significantly increased in
the uremic muscle (Figure 6d). In CKD patients, p-JNK and
p-c-Jun expressions were directly, linearly related (r¼ 0.52,
P¼ 0.017).
0
2
4
6
8
10
R
el
at
ive
 m
yo
st
et
in
 in
pr
ot
ei
n 
ex
pr
es
sio
n
R
el
at
ive
 m
yo
st
et
in
in
 R
N
A 
le
ve
l
12
Controls
Control
a
CKD Controls CKD
CKD
4
3.5
3
2.5
2
1.5
b
1
0.5
0
4.5
5
14
16
18
20
Figure 4 |Myostatin expression in healthy and CKD muscles. (a) Changes in myostatin mRNA were determined by real-time PCR.
Myostatin mRNA was upregulated in the skeletal muscle of CKD patients. Values are expressed as fold increase with respect to controls,
aPo0.05. (b) In addition, myostatin protein expression (immunohistochemistry and image analysis) was very faint in controls and
upregulated in CKD. Values are expressed as fold increase with respect to controls, bPo0.04. Myostatin displayed a diffuse signal in the
cytoplasm as well as in the nuclei (d, f, and g). In some cases an immunoreactivity of myostatin was observed on the sarcolemma
(e) (original magnification  400–1000). CKD, chronic kidney disease.
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Figure 5 | IGF-I expression in the CKD muscle and in control
subjects. (a) mRNA analysis by real-time PCR shows a clear
decrease in IGF-I levels in CKD. (b) In addition, protein analysis by
immunohistochemistry and image analysis demonstrates
suppression of IGF-I. Values are expressed as fold increase with
respect to healthy subjects, aPo0.05, bPo0.001 vs control
subjects. CKD, chronic kidney disease; IGF-I, insulin-like growth
factor-I.
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P-Akt is markedly downregulated in the muscle of CKD
patients
We used immunohistochemistry and immunoblot analysis to
examine the expression of Akt in healthy and CKD muscles.
At immunohistochemistry, in control subjects, the p-Akt
signal was clear cut and mainly diffused in muscle fibers.
Conversely, the p-Akt signal was fourfold decreased
(Po0.001) in CKD patients (Figure 7a–c). Figure 7d shows
p-Akt protein expression (western blot) in patients and
controls. P-Akt was markedly downregulated in the muscle of
patients with advanced CKD studied herein.
Determinants of apoptosis and myostatin gene expression
No association was observed between apoptosis and myo-
statin gene expression (r¼0.38; P¼NS). By univariate
linear regression analysis, apoptosis was inversely associated
with p-Akt (Table 1). LogMyostatin mRNA was directly
related to logIL-6. Using the studied variables for inclusion
into multivariate analysis models revealed LogAkt and
logIL-6 to contribute individually and significantly to the
prediction of apoptosis and myostatin gene expression
(Po0.03 and Po0.01, respectively).
DISCUSSION
The results reported in this study provide several new
observations on the biology of the skeletal muscle in CKD
patients. First, our data demonstrate that apoptotic loss of
myonuclei is enhanced. Second, myostatin gene expression is
markedly upregulated. These findings are together associated
with impaired muscle maintenance and increase the risk of
sarcopenia. Third, phosphorylated Akt is markedly down-
regulated and closely associated with the loss of myonuclei by
apoptosis, which suggests that impaired Akt signaling favors
the loss of myofibers. Finally, upregulated myostatin is
associated with IL-6 gene expression and p-JNK, suggesting
that microinflammatory changes occurring in muscle cells
are signals for myostatin regulation. Collectively, these results
show the involvement of multiple catabolic signal transduc-
tion pathways, which may promote wasting and impair
muscle regeneration.
In contrast to necrosis, which is observed in disease states,
apoptosis takes part in normal development and physiology
of the skeletal muscle.12 Sarcopenia associated with aging
seems to be the result of failure in satellite cells, which help to
regenerate skeletal muscle fibers, and the decrease in the
availability or sensitivity to growth factors, which are
necessary to maintain muscle mass and satellite cell
survival.29–32 In addition to physiology, apoptotic cell death
significantly accounts for muscle-fiber atrophy in several
neuromuscular disorders and metabolic myopathies.33 In
animal models, uremia impairs the proliferation and
differentiation of satellite cells and delays the regeneration
of the injured muscle.16 These events seem to follow CKD-
induced impaired Akt phosphorylation.16 In muscle biopsies
of patients studied herein, a few ssDNAþ /c-metþ or
ssDNAþ /myoDþ cells were observed, suggesting that most
of the apoptotic nuclei were myonuclei and that the
accelerated apoptosis is a feature interesting mainly muscle
fibers. Within this context, we have to consider that a special
feature of muscle fibers compared with other cells is that they
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Figure 6 | Expression of (a) phosphorylated JNK (p-JNK) and (c) its downstream effector, phosphorylated c-JUN (p-c-Jun) in controls
and the CKD skeletal muscle. P-JNK was strongly increased in CKD patients with respect to healthy controls. (b) Quantification of staining
intensity shows an approximately six-fold increase. Values are expressed as fold increase with respect to controls, aPo0.05. Panel c shows
detection of p-c-Jun. Compared with normal controls, in which no positive nuclei are detected, a distinct increase in the incidence on p-c-
Jun is evident in the CKD muscle. (d) P-c-Jun-positive nuclei are expressed as the percentage of positive nuclei per total nuclei (positive plus
negative, bPo0.001 vs controls). Original magnification  1000. CKD, chronic kidney disease; JNK, c-Jun amino-terminal kinase.
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are multinucleated and successive fiber segments are
controlled by individual nuclei. Each nucleus can synthesize
protein for a local domain in the vicinity of that nucleus.34,35
Therefore, apoptosis of multinucleated muscle fibers may
show some specific differences from those of mononucleated
cells, in which apoptosis directly proceeds toward cell loss. In
our study, not all nuclei along a muscle fiber revealed
apoptotic DNA fragmentation at the same time, but the anti-
ssDNA nuclear signal appeared next to the non-labeled intact
nuclei, which likely maintain cellular survival. In accordance
with this finding, and possibly also with an increase in net
protein catabolism,10 muscle-fiber CSA was reduced,
although at the borderline of statistical significance, in
patients studied herein.
In this paper, we did not address the issue of cell loss and
regeneration in satellite cells. Although the percentage of
ssDNAþ /c-metþ or ssDNAþ /myoDþ cells was similar in
patients and controls, it is possible that an imbalance between
regeneration and cell-loss processes occurs in the muscle of
patients with CKD, as demonstrated recently in the rat
muscle.16 Therefore, this issue needs to be specifically
addressed in humans.
The mechanisms underlying apoptosis in muscle physiol-
ogy and disease are largely unknown. Caspase-dependent and
caspase-independent pathways11,36 have been implicated.
There is strong evidence in animal models that the impaired
activity of the PI3-kinase/Akt pathway, by upregulating
caspase-3 and protein degradation is a regulator of muscle
atrophy in uremia.10 However, this relationship is not
understood in patients with CKD. In our study, apoptosis
was inversely associated with p-Akt, suggesting that altered
signaling through the PI3-kinase/Akt pathway causes earlier
loss of myonuclei. This observation gives further strength to
the hypothesis that altered intracellular signaling causes a
shift in the balance between pro-survival and pro-apoptotic
pathways in the muscle37 and suggests a role of metabolic
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Figure 7 |Phosphorylated Akt (p-Akt) is markedly downregulated in the muscle of CKD patients. In control subjects, the p-Akt signal
was mainly diffused in (a) muscle fiber, whereas (b) it was markedly downregulated in the muscle of patients with advanced CKD.
(c) Quantification of staining by image analysis shows significant suppression of p-Akt levels in CKD. Values are expressed as fold increase
with respect to healthy subjects, aPo0.001. Original magnification  1000. (d) Western blots of muscle lysates shows suppression of p-Akt
in CKD with respect to healthy controls. Blots were stripped and reprobed with anti-Akt antibody. The gel is representative of 10 CKD and 5
healthy subjects. The graph shows the decrease of p-Akt in CKD and it is expressed as fold increase with respect to controls, bPo0.001. CKD,
chronic kidney disease; p-Akt, phosphorylated Akt.
Table 1 | Results of the regression analyses modeling
apoptosis and myostatin in muscle cells
Univariate Multivariate
R P-value b s.e. t P-value
Dependent variable: apoptosis (model r2=0.86, Po0.023)
LogAkt 0.61 0.004 16.56 3.11 5.325 0.032
LogIGF-I mRNA 0.16 NS 1.315 2.39 0.58 NS
LogIL-6 mRNA 0.17 NS 1.53 0.707 2.17 NS
LogJNK 0.10 NS 4.63 1.91 2.415 NS
Dependent variable: log myostatin mRNA (model r2=0.89, Po0.035)
LogAkt 0.25 NS 2.509 0.939 2.675 NS
LogIGF-I mRNA 0.18 NS 0.68 0.286 2.389 NS
LogIL-6 mRNA 0.81 0.001 0.549 0.127 4.315 0.0125
LogJNK 0.33 0.28 1.286 0.4436 2.896 NS
Abbreviations: JNK, c-Jun amino-terminal kinase; IGF-I, insulin-like growth factor-I;
IL-6, interleukin-6; NS, non-significant.
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control on apoptotic processes in CKD patients. However, it
has to be underlined that the mechanisms responsible for
apoptosis were not addressed by this study. Extrinsic or
intrinsic stimuli are responsible for apoptosis.11 Extrinsic or
ligand-induced apoptosis through the tumor necrosis factor
receptor superfamily causes the activation of caspase-8 and,
consequently, that of caspase-3.11 However, we were unable
to show an association between apoptosis and the inflam-
matory mediators tested, suggesting that the initial mechan-
ism may not be dependent on the extrinsic pathway. The
mitochondrial pathway of apoptosis, an example of an
intrinsic pathway which is initiated by stimuli inside the cell,
could alternatively be studied.
The upregulation of myostatin observed in the skeletal
muscle of patients studied herein expresses a major catabolic
signal. Myostatin acts mainly as a negative regulator of
skeletal muscle mass.38 The effects of myostatin on the rodent
skeletal muscle include inhibition of protein synthesis and
MyoD expression with an increase in atrogin-1.38,39 However,
the interpretation of the direct and/or interactive effects of
apoptosis, protein turnover, and myostatin is confounded by
intricate physiological relationships between their metabolic
pathways, as observed in many studies in cell and animal
models.38,39 In this study, we observed no association
between apoptosis and myostatin gene expression, which
suggests that these different events depend on different
pathways. Although a common target of inflammation,40 the
skeletal muscle itself may express proinflammatory cytokines,
which might hinder its sensitivity to circulating or intrinsic
anabolic signals.41,42 In our study, myostatin gene expression
was associated with upregulated IL-6 mRNA, suggesting its
dependency on microinflammatory changes occurring within
the skeletal muscle. Infiltration of macrophages into the
skeletal muscle may cause cytokine release and decrease p-
Akt, as shown recently in obese, insulin-resistant subjects.43
However, in our study, muscle CD68-positive cell number
was similar in CKD patients and controls, indicating that the
inflammatory changes observed were not secondary to
inflammatory cell release, but rather were an expression of
accelerated myokine release.
JNK, a subfamily of the mitogen-activated protein kinase
superfamily, is a critical mediator of environmental stress.44
Activation of cytokine signaling through the JNK pathway is
a link between impaired insulin/IGF-I signaling and insulin
resistance,45 as upregulated JNK can inhibit IGF-I signaling
by phosphorylation and conformational changes in insulin
receptor substrate-1 downstream of the IGF-I receptor.45 The
limited presence of p-c-Jun in the normal muscle observed in
this study suggests that c-Jun activation does not have an
important role in normal human muscle physiology. On the
other hand, we observed extensive JNK and c-Jun activation
in the muscle of patients with CKD. Myostatin has been
reported to signal transduction through JNK in mouse
myoblast cell lines46 and could exert an inhibitory action on
Akt activation to induce insulin resistance in the skeletal
muscle of CKD patients.
The current study has several strengths, as it includes a
CKD cohort of non-selected patients incident for renal
replacement therapy. However, a potential limitation is that
the CKD cohort studied might represent a peculiar aged
population, at high risk for protein-energy malnutrition,
which may be not indicative of uremia per se, but may rather
express the combined events occurring in aging and renal
disease. It is interesting that both apoptosis and myostatin are
upregulated in sarcopenia of aging, suggesting that the
findings observed in patients studied herein may represent an
acceleration of processes ‘naturally’ leading to sarcopenia in
elderly subjects. Contrariwise, Wang et al.22 observed un-
changed myostatin mRNA levels in the muscle of hemo-
dialysis patients. It must be noted that patients studied by
Wang et al. were younger, without evidence of wasting
or systemic inflammation, and could likely represent younger
and healthier conditions, as compared with patients studied
herein. In addition, our patients led a sedentary lifestyle,
which per se may facilitate apoptosis.47 It is established that
exercise training in hemodialysis patients induces changes
in skeletal muscle mRNA and increases muscle IGF-I,
which may promote protein anabolism.48 It is interesting
that apoptosis is also regulated by physical exercise in the
skeletal muscle. Although apoptosis is enhanced by acute
exercise,49 it is blunted by exercise training.50 Whether
muscle apoptosis is influenced by exercise in CKD patients is
unknown.
In conclusion, our findings indicate that an accelerated
loss of myonuclei by apoptosis and an upregulation of
myostatin are observed in the skeletal muscle of patients with
CKD at an advanced stage, before the start of renal
replacement therapy. These events, in association with
changes in protein synthesis and degradation induced by
altered signaling through the PI3-kinase/Akt pathway, might
represent key mechanisms driving the onset and progression
of muscle loss.
MATERIALS AND METHODS
Patients
Starting from 5 September 2005, 22 CKD patients (16 males/6
females) scheduled for peritoneal dialysis catheter insertion were
eligible for enrolment in this protocol at the Nephrology Division
(Department of Internal Medicine, University of Genoa). Patients
younger than 18 and older than 76 years were excluded from the
study. Patients were enrolled in the study on a consecutive basis if
they did not meet the following exclusion criteria: New York Heart
Association Class III congestive heart failure, a recent (o12 months)
myocardial infarction, liver cirrhosis, infection, or diabetic nephro-
pathy. The characteristics of patients are given in Table 2. Clinically
manifest cardiovascular disease was present in nine patients (41%).
Their estimated14 glomerular filtration rate was 9±3ml/min per
1.73m2. Causes of renal diseases were hypertensive nephrosclerosis
(13 patients), chronic glomerulonephritis (5 patients), tubulointer-
stitial nephritis (3 patients), and obstructive uropathy (1 patient).
Their mean estimated protein and calorie intake were 0.9 g/kg and
28 kcal/kg, respectively. In all, 13 patients were considered
malnourished by subjective global assessment42. Albumin levels
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were low (o3.8 g/100ml) in 11 subjects, whereas body mass
index was low (o23 kg/m2) in 15 subjects. The evidence of an
inflammatory response (C-reactive protein45mg/l) was shown in
nine subjects. All subjects led a sedentary lifestyle.
The study was part of a protocol on the effects of peritoneal
dialysis on protein turnover approved by the Ethics Committee of
the Department of Internal Medicine of the University of Genoa. All
subjects were informed about the nature, purposes, procedures, and
possible risks of the study, before their informed consents were
obtained. The procedures were in accordance with the Declaration
of Helsinki Principles regarding ethics of human research.
Control biopsies were taken in 12 otherwise healthy subjects (7
males/5 females, median age 68 years, range 59–76 years, body mass
index median 25, range 20–26 kg/m2), during elective surgery for
abdominal wall hernias. Controls were selected on the basis of
having no chronic illnesses or acute inflammatory processes. In
these subjects, baseline physical examination and screening
biochemical tests of renal, hepatic, hematological, and metabolic
function (thyroid function and fasting plasma glucose) were
unremarkable.
Muscle biopsies
Muscle biopsies were obtained from the rectus abdominis muscle, at
the beginning of surgery. Immediately after each biopsy, the muscle
sample was cleaned of any visible connective and adipose tissues and
blood, and separated into three sections. Tissue (90mg) RNA was
isolated using the Qiazol Lysis reagent (Qiagen Sciences, German-
town, MD). Isolated RNA was stored at 80 1C until use. Other
sample aliquots were used for immunohistochemical staining, and
for protein (western blot) analysis. Myofiber CSAwas determined by
analyzing a region of at least 100 fibers. Digital images of stained
sections were obtained using a Leica microscope (Leica Micro-
systems GmbH, Wetzlar, Germany) equipped with a digital camera
controlled by Q500MC Software-Qwin (Leica Microsystems
GmbH).
Apoptosis assays: ssDNA immunoassay and TUNEL
After permeabilization in saponin (0.2mg/ml) and treatment with
proteinase K (5mg/ml), samples were heated at 56–60 1C in 40%
formamide (v/v) and then stained with anti-ssDNA monoclonal
antibody (Bender MedSystems, Vienna, Austria) for 30min. Slides
were developed and analyzed as described previously.51 In situ
detection of apoptosis in the muscle was performed by TUNEL assay
using FragEL DNA fragmentation detection kit (Calbiochem, San
Diego, CA). Non-apoptotic nuclei appear counterstained with
methyl green. Positive nuclei were counted at high power
( 400–1000). The number of nuclei was expressed per whole
muscle section.51 Apoptosis was calculated as TUNEL/ssDNA-
positive cells as a function of total numbers of nuclei.51
mRNA analysis
RNA concentration and integrity of each sample were evaluated on a
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE). In all, 1 mg RNA was used for cDNA synthesis
with Improm II reverse transcriptase (Promega, Madison, WI). PCR
amplification was performed in a 20ml volume, including
specific PCR primers and a TaqMan FAM dye-labeled MGB
probe (Hs00174131_m1 (IL-6); Hs00193363_m1 (myostatin);
Hs01547656_m1 (IGF-I); Hs99999903_m1 (b-actin,). Primers and
probes were synthesized by Applied Biosystems Applera Italia
(Monza, Italia). Assays were run in triplicate with Universal PCR
Master Mix on MasterCycler realplex (Eppendorf, Hamburg,
Germany) PCR system. To quantify target mRNA abundance,
differences in threshold cycles between the gene target and b-actin
were calculated, and then relative mRNA abundance was calculated
using the 2DDCt method.
Western blot
Tissues were homogenized and lysed in lysis buffer (20mmol/l
HEPES, 150mmol/l NaCl, 10% (v/v) glycerol, 0.5% (v/v) NP40
(Nonidet-P40), 1mmol/l EDTA (ethylenediaminetetraacetic acid),
2.5mmol/l DTT (dithiothreitol), 10 mg/l aprotinin, leupeptin,
pepstatin A, 1mmol/l PMSF (phenylmethanesulfonyl fluoride),
and Na3VO4 (Sigma-Aldrich S.r.L, Milan, Italy). Protein concentra-
tion was determined by Coomassie protein reagent (Pierce, Rock-
ford, IL) and 50 mg was resolved on SDS-polyacrylamide gels and
electrotransferred into a nitrocellulose membrane (GE Healthcare,
Buckinghamshire, England). Blots were blocked for 1 h at room
temperature in phosphate-buffered saline (5% non-fat dry milk)
and then probed using anti-human phospho-Akt 1/2/3 (Thr 308)
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
overnight at 4 1C. Membranes were incubated for 1 h in horseradish
peroxidase secondary antibodies (Santa Cruz Biotechnology).
Immunoblots were developed with Immobilon western chemilumi-
nescent horseradish peroxidase substrate (Millipore, Billerica, MA).
The membranes were stripped and reprobed with polyclonal Akt
1/2/3 (Santa Cruz Biotechnology) for normalization of the loading.
Band intensities were determined using IAS 2000 software from
Delta Sistemi (Latina, Italy).
Histological preparation and immunohistochemical staining
Paraffin sections (5mm) of 2% paraformaldehyde-fixed muscle
were deparaffinized, hydrated, and treated with 3% H2O2 in
methanol. Each sample was analyzed for the detection of apoptosis
and expression of p-Akt, p-JNK, and p-c-Jun (monoclonal
antibodies, Santa Cruz Biotechnology), IL-6 and c-Met (polyclonal
antibodies, Santa Cruz Biotechnology) myostatin (polyclonal anti-
body; Novus Biologicals, Littleton, CO), IGF-I (clone Sm 1.2, mouse
monoclonal antibody; Upstate, Lake Placid, NY), CD68 (Dako,
Table 2 | Clinical characteristics of patients with chronic
kidney disease (CKD)
Controls CKD patients
Number of subjects 12 22
Age (years) 68 (59–76) 69 (53–76)
Gender (M/F) 7/5 16/6
BMI (kg/m2) 25 (20–26) 25 (19–28)
nPNA (g/kg) 1.0±0.1 0.9±0.1
SGA score 7 (6–7) 5 (2–6)*
CRP (mg/l) 4 (3–7) 9 (3–45)*
eGFR (ml/min per 1.73m2) 100±5 8±3a
[HCO3]
 (mmol/l) 24 (22–26) 24 (22–26)
Albumin (g/dl) 4.2 (3.9–4.6) 3.9 (2.6–4.6)
Hemoglobin (g/dl) 14±1 11.2±0.3*
BUN (mg/dl) 12±2 99±3**
Abbreviations: BMI, body mass index; BUN, blood urea nitrogen; CRP, C-reactive
protein; eGFR, estimated glomerular filtration rate; F, female; M, male; nPNA,
normalized protein nitrogen appearance; SGA, subjective global assessment.
Data are mean±s.e.m. or median (range).
Significance of difference vs control subjects: *Po0.05; **Po0.01.
aNot tested.
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Glostrup, Denmark), and MyoD (monoclonal antibody; Millipore).
Sections were incubated overnight in primary antibody at room
temperature, followed by incubation in biotinylated antibody for
30min. Immunostaining was completed by incubation for 30min
with streptavidin–peroxidase. The biotin–streptavidin–peroxidase
method (Vector Laboratories, Burlingame, CA) was performed as
described previously.52,53 The expressions of p-Akt, p-JNK,
myostatin, and IL-6 were examined by image analysis and expressed
as positive areas (Leica Q500 MC Image Analysis System, Leica,
Cambridge, UK).53 For apoptosis and p-c-Jun, an average of B200
nuclei was counted in controls and uremic patients. Muscle-fiber
CSA was determined in 5-mm paraffin sections by image analysis.
For each sample, at least 100 fibers were measured.
Statistical analysis
All data are presented as mean±s.e.m. or median (range). Statistical
analysis was performed using the SPSS statistical package (version
16; SPSS, Chicago, IL). For statistical analysis of expression variables
that did not have a Gaussian distribution, values were logarith-
mically transformed or analyzed by non-parametrical tests.
Comparisons between groups were performed by one-way ANOVA
(analysis of variance) with a post hoc Bonferroni’s correction or by a
Kruskal–Wallis non-parametric test when appropriate. A multi-
variate regression model was created to study the predictors of
myostatin or apoptosis. Statistical significance occurred at a
computed two-tailed Po0.05.
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